Pfizer's new Xeljanz formula powers forward; Boehringer team nabs digital comms award; AbbVie med gets special NHS commission;

> Pfizer ($PFE) said the FDA accepted its application for a new once-daily dose of its JAK inhibitor Xeljanz, as a second-line treatment for rheumatoid arthritis. Release

> Boehringer Ingelheim's Not Just One Disease blog at ASCO 2014 picked up a digital communications prize in London; Ogilvy HealthPR spearheaded the effort. Report

> AbbVie's ($ABBV) Parkinson's disease drug Duodopa won approval from England's National Health Service via a new commissioning policy, which will streamline prescribing; the med was previously only available via a case-by-case funding request. Report

> Gilead Sciences ($GILD) filed for FDA approval for its latest triple-drug therapy for HIV; approval could come as early as this year. Report

> Since its new CMO joined Johnson & Johnson ($JNJ) in 2013, the company has focused on data to tailor its marketing and advertising. Report

And Finally... University of Pennsylvania researchers may have identified how small DNA differences affect the effectiveness and safety of thiazolidinedione meds for diabetes. Report

Suggested Articles

AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.

Roche’s Genentech new innovation targets cancer cells via video game to raise awareness of personalized medicine, tumor types and biomarker testing.

Alexion is undergoing a major makeover by moving away from ultra-rare diseases, but it still has more to pursue in an effort to back up Soliris.